MediciNova, Inc.
MNOV
Positions held
Your positionsMNOV isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $75.80M | Enterprise value | $50.50M | Trailing P/E | — | Forward P/E | -2.99 |
| PEG | — | Price / book | 2.03 | Beta | 0.61 | Dividend yield | 0.00% |
| Revenue growth | 2.4% | Earnings growth | — | Gross margin | 37.7% | Operating margin | -5.5% |
| Profit margin | 0.0% | ROE | -25.6% | ROA | -16.4% | Debt / equity | 0.00 |
| Current ratio | 8.75 | Free cash flow | -$5.74M | Analyst recommendation | strong_buy | Mean target | $8.25 |
| 52w high | $3.90 | 52w low | $1.17 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.5M | $0.2M | $0.2M | $0.1M | $0.1M | — |
| Op margin | -554.3% | -1516.6% | -2038.0% | -2741.7% | -2679.9% | — |
| Net income | -$2.3M | -$2.6M | -$2.8M | -$3.1M | -$3.3M | — |
| Gross margin | 69.3% | 9.0% | 3.1% | 6.5% | 13.6% | — |
| Gross profit | $0.3M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Operating income | -$2.5M | -$2.8M | -$3.1M | -$3.4M | -$3.6M | — |
- Revenue +145% vs prior quarter ($0.5M vs $0.2M).
- Gross margin 69.3% (was 9% prior quarter).
- Operating margin expanded to -554.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.4M | $0.0M | $1.0M | $0.0M |
| Op margin | -3242.5% | — | -990.0% | — |
| Net income | -$12.0M | -$11.0M | -$8.6M | -$14.1M |
| Gross margin | 7.6% | — | — | — |
| Gross profit | $0.0M | $0.0M | — | — |
| Operating income | -$13.3M | -$12.7M | -$9.9M | -$14.6M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · MediciNova to Participate in the Maxim Growth Summit
2026-09-28 · MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
2026-09-28 · MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints
2026-09-28 · MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
2026-09-28 · Top Premarket Decliners
2026-09-28 · MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2026-09-25 · MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
2026-09-17 · Top Midday Gainers
2026-09-08 · MediciNova to Participate in Two Investor Conferences in September
2026-08-13 · MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates
2026-08-13 · MediciNova: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patterns